Explore the Agenda
Pre-Conference Day
Tuesday, July 28
Day One
Wednesday, July 29
Day Two
Thursday, July 30
8:00 am Check-In & Light Breakfast
9:00 am Workshop A
Connecting Linker & Conjugation Chemistry to Clinical Efficacy & Safety Through Integrated Biological Insight into the Tumor Microenvironment Pharmacokinetics & Pharmacodynamics
Diving into the critical bridge between chemical innovation and clinical success, this workshop addresses the identified gap in biological validation. Moving from in vitro chemistry too predictable in vivo performance requires chemists and biologists to collaboratively design ADCs with an optimized therapeutic index from the outset.
This is a must-attend for chemistry and protein engineering teams looking to ground their technical strategies in biological reality and improve translatability by:
- Correlating specific linker chemistries and conjugation sites with tumor microenvironment biology and patient-specific PK/PD data to build predictive models for how chemical modifications influence clearance rates, tumor exposure, and ultimately efficacy and safety margins
- Designing and interpreting relevant in vivo and ex vivo studies to validate novel linker or conjugation technologies, moving beyond simple stability assays to demonstrate a direct impact on widening the therapeutic window in resistant or sensitive tumor model
- Establishing a framework for early-stage decision-making that integrates analytical chemistry data, in vitro potency, and preliminary PK insights to select the most promising ADC candidate for further development, de-risking the path to the clinic
12:00 pm Lunch Break & Networking
1:00 pm Workshop B
Exploring How to Innovate Linker Technologies & Conjugation Chemistry to Reengineer Traditional Payloads & Maximize Therapeutic Index for Safer, More Potent ADCs
Focusing on the high-value challenge of improving established cytotoxins, this hands-on workshop tackles the "why now" of evolving chemistry for traditional payloads. Providing a tactical playbook for leveraging next-generation linker design and site-specific conjugation to overcome the limitations of first-generation ADCs and achieve best-inclass profiles.
This is a must-attend for teams looking to maximum the value of proven payloads by understanding that where you attach is as important as what you attach by:
This workshop will gather experts to discuss:
- Systematically evaluating how strategic changes to the conjugation site impact critical attributes such as antibody stability, antigen binding, and off-target toxicity profiles
- Benchmarking novel linker designs, from peptide-based to hydrophilic polymer shields to assess their ability to improve solubility, reduce aggregation, and enable higher DARs without compromising tolerability in traditional payloads.
- Building a comparative case study on site-specific vs. stochastic conjugation for a traditional payload, analyzing hard data on homogeneity, pharmacokinetic consistency, and manufacturability to justify the investment in advanced conjugation technologies